About StemCells, Biomedicine, Diet Impact, Mental Health, Meditation,Viruses & Regenerative Medicine

[north40000]

Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported today a publication from the University of Miami1, demonstrating intravenous administration of JadiCells results in a significant survival improvement in COVID-19 patients. The Phase 1/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells™ intravenously at days 0 and 3, and 12 patients received placebo control. At 28 days 91% of JadiCell™ treated patients survived whereas only 42% of patients in the placebo group survived. There were no adverse effects associated with JadiCell™ administration.

The rest of the story:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159169486